Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Hospira
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Worldwide sales in 2014 were approximately $4.5 billion. Current results are now part of Pfizer's consolidated statements.
In January 2004, Abbott announced it was spinning off its hospital products division.
Hospira's name was picked by employee vote. The name is derived from the words "hospital," "spirit," "inspire," and spero, a Latin word meaning "hope."[dead link] Hospira became an independent company on May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.
In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion.
In 2009, Hospira acquired the biotechnology business from Pliva-Croatia, the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009. In 2010, Hospira acquired Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million.
In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball became CEO in March 2011. Hospira named John Staley its non-executive chairman with the retirement of former executive chairman Christopher Begley in January 2012. Begley had announced his retirement as Hospira's chief executive in August 2010, but had remained as executive chairman.
In 2015, Pfizer signed an agreement to acquire Hospira. The roughly $17 billion acquisition was completed in September, 2015. A year later Pfizer sold the medical devices portion of Hospira to ICU Medical for roughly $900 million in cash, stock, and other consideration.
Hub AI
Hospira AI simulator
(@Hospira_simulator)
Hospira
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Worldwide sales in 2014 were approximately $4.5 billion. Current results are now part of Pfizer's consolidated statements.
In January 2004, Abbott announced it was spinning off its hospital products division.
Hospira's name was picked by employee vote. The name is derived from the words "hospital," "spirit," "inspire," and spero, a Latin word meaning "hope."[dead link] Hospira became an independent company on May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.
In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion.
In 2009, Hospira acquired the biotechnology business from Pliva-Croatia, the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009. In 2010, Hospira acquired Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million.
In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball became CEO in March 2011. Hospira named John Staley its non-executive chairman with the retirement of former executive chairman Christopher Begley in January 2012. Begley had announced his retirement as Hospira's chief executive in August 2010, but had remained as executive chairman.
In 2015, Pfizer signed an agreement to acquire Hospira. The roughly $17 billion acquisition was completed in September, 2015. A year later Pfizer sold the medical devices portion of Hospira to ICU Medical for roughly $900 million in cash, stock, and other consideration.